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Progenics's rCD4-IgG2 (PRO-542) is a recombinant fusion
protein, which has been developed using the company's Universal
Antiviral Binding (UnAB) technology, and is in phase I/II clinical
trials for the treatment of human immunodeficiency virus type I
(HIV-1) infection [273391].
At the beginning of 1997, Progenics received a Phase II Small
Business Innovation Research Program (SBIR) grant from the
National Institute of Allergy and Infectious diseases (NIAID) to
fund the development of PRO-542 [236048]. A further grant of
$2.7 million was awarded in August 1998 for the clinical
evaluation of PRO-542 and other anti-HIV therapies [294200].
Progenics is collaborating with the Aaron Diamond AIDS
Research Center (ADARC) in New York and the Center for
Disease Control and Prevention in Atlanta [178410]. In February
2000, Progenics and Genzyme Transgenics Corp signed an
agreement to continue the development of a transgenic source of
PRO-542. Genzyme will develop transgenic goats that produce
PRO-542 in their milk in exchange for undisclosed fees and
milestone payments. Genzyme will supply PRO-542 to Progenics
for clinical trials with a possibility for eventual commercial supply
[357291]. Following on from this, in October 2000, Progenics
received an SBIR grant to fund a two-year project with Genzyme
Transgenics into the development of cost-effective methods for the
manufacture of PRO-542, by optimization of the production of the
drug in the milk of transgenic dairy animals [385982].
In August 2000, Punk, Ziegel & Company predicted that
Progenics Pharmaceuticals will become sustainably profitable in
2003 following the launch of PRO-542 and GMK (Progenics
Pharmaceuticals) in 2002 [390063].
Introduction
PRO-542 is a universal antiviral-binding (UnAB)-based
therapy. UnAB units are genetically engineered antiviral
molecules that mimic permissive cell surface attachment
regions. PRO-542 is a hybrid protein, incorporating the HIV-
binding region of CD4, which is required by HIV to attach to
host cells (T-cells) and initiate infection [383657]. PRO-542
acts as an attachment inhibitor, by binding to a viral surface
glycoprotein, gp120, thus preventing HIV from attaching to
the CD4 molecules on T-cells.
Since the discovery of HIV-1 interaction with CD4, several
therapeutic strategies have been employed for the
prevention and treatment of HIV-1 utilizing CD4-based
therapeutics  [383655], [383666].  A soluble form of CD4,
Originator Progenics Pharmaceuticals Inc
Licensees Aaron Diamond AIDS Research Center;
Genzyme Transgenics Corp
Status Phase II Clinical
Action HIV-binding agent
Indication Acquired immune deficiency syndrome, HIV
infection
Biotechnology Protein (Fusion)
Synonyms Antibodies (HIV), Progenics, rCD4-IgG2
termed sCD4, was developed as a 'molecular decoy' that
binds to HIV-1 gp120 and inhibits viral attachment, as well
as subsequent infection [383669]. In phase I clinical trials,
sCD4 demonstrated a good safety profile; however, its
antiviral effect was not well pronounced, probably due to a
short half-life (45 min in humans following iv
administration) [383679]. A dimeric CD4-human IgG1 heavy
chain fusion protein has also been described [383634], which
has a longer half-life, as well as in vitro antiviral activity
[383636]. Development of this molecule was halted,
however, due to potential drawbacks of Fc receptor-
dependent complement activation [383634], [383637] and
transfer of recombinant human CD4-IgG across the placenta
[383677]. CD4-IgG2 conjugate (PRO-542) was developed to
overcome the potential problems associated with half-life
and Fc receptor-mediated complement activation. It has a
longer half-life and does not interact with the high-affinity
Fc receptors on human monocytic U937 cells [383593].
PRO-542 has been developed for use in two clinical settings:
(i) post-exposure prophylaxis and (ii) immunotherapy. In
post-exposure prophylaxis therapy, PRO-542 would protect
exposed individuals from contracting HIV infection by
reducing the concentration of infectious virus in the
bloodstream. As an immunotherapy, PRO-542 could be used
to treat HIV infection, especially during the early or
asymptomatic phase of infection [178410], [278442].
Synthesis and SAR
PRO-542 is a fusion protein comprising human IgG2 in
which the Fv portions of both heavy and light chains have
been replaced with four copies of the D1 and D2 domains of
human CD4 [341870], [383593], [383659]. PRO-542 has been
expressed in Chinese hamster ovary (CHO) cells, where it is
secreted as a fully assembled heterotetramer, and purified
using size-exclusion chromatography. Its tertiary structure
was determined based on its high binding affinity for
recombinant soluble gp120 from both laboratory-adapted
and primary isolates of HIV-1 [383593].
PRO-542 was designed to bind multiple copies of gp120, and
appears to be able to neutralize HIV by crosslinking up to
four gp120s on the surface of one or more virus particles.
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Electron microscopy has been used to visualize PRO-542
alone and complexed with gp120 viral envelope
glycoprotein that protrudes from the virus. These studies
confirmed the structural flexibility of PRO-542 and its
complexation with four molecules of gp120 [366535]. PRO-
542 acts by two mechanisms: (i) by high-affinity binding to
gp120; and (ii) by detaching gp120 from the HIV particle,
thereby inactivating the virus [178410].
In order to produce sufficient quantities of the antibody-like
molecule in a cost effective manner, Progenics
Pharmaceuticals initiated a program in 1998 with Genzyme
Transgenics Corp to develop a means of expressing PRO-542
in the milk of transgenic animals [278442], [279692].
Pharmacology
PRO-542 has been developed as an immunoprophylactic
agent for reducing the probability of infection after HIV-1
exposure [383593], [383650]. Binding of PRO-542 to
glycoprotein gp120 is the basis of HIV-1 neutralization. It
has been observed that PRO-542 binds at nanomolar
concentrations to purified gp120 isolated from both primary
and laboratory-adapted HIV-1 isolates [383593]. In rabbits,
PRO-542 has a terminal half-life of 26.4 h, compared to mean
terminal serum half-lives in humans of 4.2 ± 0.9 and 3.3 ± 0.7
days for 5 and 10 mg/kg doses, respectively [383593],
[383659].
On the basis of flow cytometric analysis, PRO-542 does not
appear to bind to Fc receptors, a property that is desirable
since an agent with FcR-binding capability will be lethal for
uninfected cells bearing this surface receptor. PRO-542
inhibits syncytia formation in HIV-1-infected cells,
suggesting that it would successfully prevent cell-to-cell
HIV-1 transmission [383593]. Furthermore, it was effective
against diverse laboratory-adapted and primary HIV-1
isolates, including strains with different tropisms and
isolated at different stages of disease [383650], [383652]. In a
hu-PBL-SCID mouse model, passive administration of PRO-
542 10 mg/kg, protected animals against subsequent
infectious doses of laboratory-adapted T-cell-tropic isolate
HIV-1 (LAI), while a 50 mg/kg dose protected four out of
five mice against the primary isolates HIV-1 (JR-CSF) and
HIV-1 (AD6) [383652].
The synergistic inhibition of HIV-1 using combinations of
PRO-542 and other antiviral agents has also been
investigated [374349], [378084], [380352], [381776], [382628].
A combination of PRO-542 and T-20 (pentafuside; Duke
University/Trimeris Inc) was especially potent in blocking
HIV entry into cells. T-20 is derived from gp41. The activity
of each agent, both of which are termed 'entry inhibitors',
was greatly enhanced by the presence of the other, resulting
in synergistic or supra-additive antiviral effects. In in vitro
studies, PRO-542 and T-20 synergistically blocked both
virus-to-cell and cell-to-cell spread of HIV; the levels of each
agent required to achieve biologically relevant inhibition
were reduced by approximately 10-fold [374349], [381776].
PRO-542 was also tested in combination with T-20 and PRO-
140 (Progenics Pharmaceuticals), each of which inhibits a
different step in the sequence of events leading to the entry
of HIV into target cells. PRO-140 is a monoclonal antibody
to CCR5, which potently blocks HIV-1 entry but not CC-
chemokine signaling through CCR5. Potent synergies were
observed for certain combinations of these HIV-1 inhibitors.
In such instances, the drug levels required to achieve
clinically relevant levels of inhibition were reduced 5- to 15-
fold and no agent antagonized the activity of another
[378084], [380352], [382628].
Metabolism
In a phase I clinical trial in which PRO-542 0.2 to 10 mg/kg
was administered iv to HIV-infected adults, the area under
the concentration-time curve and peak serum concentrations
increased linearly with dose, and the terminal serum half-
life was 3 to 4 days [383659].
Toxicity
One of the potential concerns for recombinant fusion protein
therapeutics is unintentional product reactivity. Phase I trial
data in HIV-infected adults supported the non-
immunogenic nature of PRO-542 [341870]. In this study, the
drug was well tolerated and no dose-limiting toxicities were
identified [341870], [383659].
Clinical Development
Phase I/II
A single-dose phase I/II study was conducted at the Mount
Sinai Medical Center, NY, USA, evaluating the safety,
pharmacology and antiviral activity of PRO-542 in HIV-1
infected adults (with criteria of viral load ≥ 3000 copies/ml
of viral RNA, CD4 counts > 50 cells/mm3 and stable or not
receiving anti-HIV therapy) [341870], [375598], [383659]. In
this study, individuals were treated with one of four doses
of PRO-542 (0.2, 1.0, 5.0 or 10.0 mg/kg body weight).
Patients in the high-dose group reached a serum
concentration of > 500 µg/ml and experienced a statistically
significant reduction in plasma HIV RNA; the reductions in
infectious HIV plasma levels were sustained [341870],
[341337], [375598], [383659].
A second multicenter phase I/II study was carried out in
pediatric patients at Baylor College of Medicine in Houston,
TX, the University of California at San Francisco, CA and the
University of Pennsylvania, PA, by the AIDS Clinical Trials
Group (ACTG) [284326], [354249]. In one of these multi-dose
trials, 18 HIV-1-infected children were treated with a single
infusion or 4 weekly doses of PRO-542. The six children
treated weekly with PRO-542 all demonstrated a decrease in
HIV RNA of up to 1.5 log10. Three of the children showed
sustained reductions in viral loads that persisted for as long
as 14 days post-treatment [354249], [374349]. No serious
drug-related adverse events were observed.
PRO-542 has now completed these two phase I/II clinical
trials [383541].
Side Effects and Contraindications
Single-dose iv administration of 0.2 to 10 mg/kg of PRO-542
was well tolerated and no significant drug-related adverse
events were reported [341870]. No patients developed
antibodies to PRO-542 [383659]. PRO-542 was also well
tolerated in pediatric clinical trials [374349].
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AIDS and HIV infection represent one of the most serious
health threats facing mankind. Currently, highly active
antiretroviral therapy (HAART) is considered the most
promising therapeutic option, although a number of studies
document residual virus in HAART patients [383681]. UnAB
technology, and specifically PRO-542 with its novel mode of
action [383657], represents an interesting approach to the
treatment of HIV and AIDS. Monotherapy with PRO-542 in
phase I/II clinical trials in HIV-infected adults and children,
demonstrated good safety, tolerability, pharmacokinetics
and reduction of HIV RNA levels [284326], [341870],
[374349], [375598], [383659]. With the recent completion of
phase I/II clinical trials, and the fact that Progenic
Pharmaceuticals are collaborating with Genzyme
Transgenics for the development of a transgenic source of
PRO-542 (goats milk), with a possibility for eventual
commercial supply [357291], indicates that the company are
continuing the clinical development of this therapy.
A serious challenge to PRO-542, however, is CD4-
independent infection, which suggests that gp120
interaction with CD4 surface molecules is not necessary for
infection in certain cell types [383671]. In addition, it is also
important to consider previous studies that show that the
virus envelope proteins are not required for virus
attachment [383675].
In vitro studies of combination therapies, ie, PRO-542 + T-
20 and PRO-542 + T-20 + PRO-140, show that these double-
and triple-drug cocktails act synergistically and potently
[374349], [378084], [380352], [381776], [382628]. The key to
these combination therapies is that each individual drug
acts at a different step in the sequence of events leading to
HIV entry/infection of host cells [382628]. It will be
interesting to see how the PRO-542-combination therapies
compare with traditional HAART programs currently
under investigation and in use.
Licensing
Aaron Diamond AIDS Research Center
Progenics Pharmaceuticals Inc and Aaron Diamond AIDS Research Center are collaborating on the development of PRO-542
[178410].
American Cyanamid Co
American Cyanamid and Progenics agreed to collaborate on the study of several agents combining the use of Progenics HIV
Universal Neutralizing Antibody technology (UnAB) with drug conjugates [167582].
Genzyme Transgenics Corp
Progenics and Genzyme Transgenics have signed an agreement to continue the development of a transgenic source of supply
for PRO-542. Genzyme will develop transgenic goats that produce PRO-542 in their milk in exchange for undisclosed fees
and milestone payments [357291].
Development History
Developer Country Status Indication Date Reference
Aaron Diamond AIDS Research Center US C2 AIDS 06-JAN-98 273391
Progenics Pharmaceuticals US C2 AIDS 06-JAN-98 273391
Literature classifications
Key references relating to the technology are classified according to a set of standard headings to provide a quick guide to
the bibliography. These headings are as follows:
Biology:  References which discuss synthesis and structure-activity relationships.
Clinical: Reports of clinical phase studies in volunteers providing, where available, data on the following: whether the
experiment is placebo-controlled or double- or single-blind; number of patients; dosage.
Biology
Study Type Effect Studied Experimental Model Result Reference
In vivo Neutralization of primary
HIV-1 isolates.
hu-PBL-SCID mice. PRO-542 10 mg/kg protects all
animals against challenge with
laboratory-adapted T-cell-tropic
isolate HIV-1 (LAI), while 50 mg/kg
protected 4/5 mice against the
primary isolates HIV-1 (JR-CSF) and
HIV-1 (AD6).
383652
In vitro gp120 Binding affinity. Laboratory-adapted strain and a
primary isolate of HIV-1.
PRO-542 has nanomolar binding
affinity.
383593
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Biology (continued)
Study Type Effect Studied Experimental Model Result Reference
In vitro Inhibition of syncitium
formation.
Virus-free HIV-1 envelope
glycoprotein.
Tetrameric CD4-IgG2 (PRO-542)
inhibited syncitium formation more
effectively than monomeric sCD4 or
dimeric CD4-γ 2 fusion protein.
383593
In vivo Pharmacokinetics. Rabbit. Plasma terminal t½ = 26.4 h. 383593
In vitro Synergistic inhibition by
PRO-542 + T-20.
Preclinical models of HIV-1
infection.
Good synergy over a range of
concentrations, reducing the drug
levels required. Drug levels required
for clinically relevant inhibition
reduced by ∼ 10-fold.
374349
381776
In vitro Synergistic inhibition by
PRO-542 + T-20 + PRO-
140.
Preclinical models of HIV-1
infection.
Good synergy observed for certain
combinations. Drug levels required
for clinically relevant inhibition
reduced by 5- to 15-fold.
378084
380352
382628
Clinical
Study Type Effect Studied Result Reference
Phase I/II. Single-dose safety,
pharmacology and antiviral
activity in HIV-1-infected adults.
PRO-542 0.2 to 10 mg/kg iv was well tolerated,
no dose-limiting toxicity observed, terminal t1/2 = 3
to 4 days. Evidence of antiviral activity observed
as reductions in plasma HIV RNA and plasma
viremia.
341337
341870
383659
Phase I/II. 18 HIV-1-infected children,
treated with a single infusion or 4
weekly doses of PRO-542.
All six children receiving weekly doses showed
decreased plasma HIV-1 RNA (up to 1.5 log10).
Three of the children showed sustained
reductions in viral load that persisted for as long
as 14 days post-treatment. No serious drug-
related adverse events were reported.
354249
374349
Associated Patent
Title  Compounds capable of inhibiting HIV-1 infection.
Assignee  Progenics Pharmaceuticals Inc
Publication  WO-09726009 24-JUL-97
Priority  US-1996-587458 17-JAN-1997
Inventors  Maddon PJ, Allaway GP,  Liwin V
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